Autoanticorpos em esclerose sistêmica e sua correlação com as manifestações clínicas da doença em pacientes do Centro-Oeste do Brasil

Horimoto, Alex Magno Coelho; Costa, Izaías Pereira da

doi:10.1016/j.rbr.2014.09.007

Cited by 3 publications

(6 citation statements)

References 39 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to other populations, i.e. U.S and French [30], Mexican [31], German Network [16], EULAR 1 Scleroderma Trials And Research (EUSTAR) group [13], and the mid-western region of Brazil [32], patients in the current study were mostly female.…”

Section: Discussion_____________________________supporting

confidence: 66%

“…Consistent with these studies, the current results demonstrated that 5.19% of SSc patient were anti-RNAP III positive. However, two studies showed U.S and Brazil SSc patients were 25% and 15.2% anti-RNAP III positive, respectively [30,32]. 1 The European League Against Rheumatism Taken together, the current data showed that anti-RNAP III and ATA were higher in dcSSc patients, whereas ACA was higher in lcSSc patients.…”

Section: Discussion_____________________________mentioning

confidence: 47%

“…ACA is directed against centromere proteins, and it has been detected in 20-25% of SSc populations that are strongly correlated with lcSSc [27]. The frequency of ACA in different studies varies from 4-52.2% [16,[30][31][32][33][34], although in a study of Japanese patients by Kuwana et al, 93% were ACA positive [6]. In the current study, the frequency of ACA, which is more associated with lcSSc [9,10], was low and 6.09% were ACA positive.…”

Section: Discussion_____________________________mentioning

confidence: 99%

“…Different studies on different ethnic groups have reported 13-41.2% ATA positivity [16,[30][31][32][33][34]. In a study of Japanese patients by Kuwana et al, 66% were ATA positive [6].…”

Section: Discussion_____________________________mentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of Autoantibodies in patients with Systemic Sclerosis

et al. 2020

View full text Add to dashboard Cite

Systemic sclerosis (SSc, scleroderma) is a multisystemic chronic autoimmune connective tissue disorder characterized by extensive fibrosis, vascular abnormalities, and immune dysfunction [1]. The exact etiopathogenesis of SSc remains unknown, although in genetically susceptible individuals, environamental triggers and dysregulated epigenetic changes contribute to the development of SSc [2]. Systemic sclerosis is more prevalent in black people; however, it is found in all racial groups and all geographic regions [3]. A serological hallmark of systemic sclerosis is the presence of serum autoantibodies against various intracellular antigens. Autoantibodies have been observed at first diagnosis in more than 95% of patients affected with systemic sclerosis [4]. Each of the autoantibodies is beneficial in the diagnosis of affected patients. Different autoantibodies have been associated with different disease subtypes and with differences in disease severity, including the extent of skin involvement, internal organ manifestations, as well as determining the prognosis [5]. All of these antibodies are directed against structures within the nucleus of the cell and, thus, are ANAs. Some ANAs, including ACA, ATA/anti-Scl-70 antibody, antifibrillarin/anti-U3-ribonucleoprotein (AFA), anti-PM/Scl antibody, anti-Th/To antibody, and anti-RNAP III are found in the sera of systemic sclerosis patients [4]. Original Article Open Access Systemic sclerosis is an autoimmune disease clinically characterized by vascular and immune dysfunction, leading to fibrosis that can damage multiple organs. The presence of non-overlapping SSc-associated autoantibodies best presents the autoimmune nature of systemic sclerosis. The primary purpose of this study was to investigate the autoantibody profile in Iranian patients with systemic sclerosis. Sera from 481 patients with systemic sclerosis were collected from 2013 to 2016. Levels of anti-nuclear antibodies (ANA) were quantitatively detected using the indirect immunofluorescence (IIF) method, and levels of specific autoantibodies including anti-topoisomerase I antibody (ATA), anti-centromere antibody (ACA) and anti RNA polymerase III antibody (anti-RNAP III) were determined qualitatively using the enzyme-linked immunosorbent assay (ELISA) technique. Among all patients evaluated, a predominance of females (86.7%) was found, and 434 (90.2%) patients showed positive ANA results by IIF. ANA was detected in 87.3% and 92.0% of limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) patients, respectively, which was not significantly different. The frequency of anti-RNAP III, ACA, and ATA was 5.19%, 6.09%, and 72.3%, respectively. Furthermore, anti-RNAP III, ATA, and ANA levels were correlated with dcSSc, whereas ACA levels were correlated with lcSSc. It was confirmed that ATA expression is significantly higher in dcSSc patients. This study had a lower frequency of ACA (6.09%) than most previous cohorts. The results demonstrated that the clinical subtype of systemic s...

show abstract

Section: Discussion_____________________________supporting

confidence: 66%

Section: Discussion_____________________________mentioning

confidence: 47%

Section: Discussion_____________________________mentioning

confidence: 99%

“…Different studies on different ethnic groups have reported 13-41.2% ATA positivity [16,[30][31][32][33][34]. In a study of Japanese patients by Kuwana et al, 66% were ATA positive [6].…”

Section: Discussion_____________________________mentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of Autoantibodies in patients with Systemic Sclerosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Likewise, ATA was the most frequently identified autoantibody in several European, American and Maghreb countries, with a higher frequency in Algeria compared with Morocco and Tunisia. In contrast, Brazil reported a lower rate of ATA but a higher rate of antinuclear antibodies (ACAs), reflecting the presence of a limited rather than a diffuse form of SSc [ 23 ]. Indeed, ACA is the most frequent autoantibody in Brazil (52.2%) and the second in the USA and Mexico (29.5% and 20%, respectively), owing to the high frequency of the lcSSc form in American countries.…”

Section: Discussionmentioning

confidence: 99%

Clinical and serological correlation of systemic sclerosis in Moroccan patients

Ouazahrou

Bakkouri

Souali

et al. 2023

Rheumatology Advances in Practice

View full text Add to dashboard Cite

Objective Systemic sclerosis (SSc) is a connective tissue disorder characterized by excessive fibrosis of the skin and internal organs, along with microvascular damage, and is often associated with typical autoantibodies. This study aimed to analyze the correlation between specific autoantibody profiles, clinical and paraclinical features in Moroccan patients with SSc. Methods We analyzed the presence of specific autoantibodies in 46 SSc patients using indirect immunofluorescence (IIF) on Hep-2 cells and immunodot. We then correlated the type of autoantibodies with clinical and laboratory manifestations. Results Among our patients, 86.9% were females. The mean age of patients at diagnosis was 50.21 years old, with an average diagnosis delay of 5 years. The main clinical manifestations found were Raynaud’s phenomenon (89.2%), sclerodactyly (84.8%), proximal scleroderma (67.4%), gastrointestinal involvement (50%), and interstitial lung disease (30.4%). According to the specific autoantibody profile, 14 patients were anti-topo I positive (30.4%), 8 were anti-RNP(68kDa/A/C) positive (17.4%) and 6 were anti-RNA polymerase III positive (13%). We found a significant association of Anti-RNAP III with sclerodactyly and pulmonary arterial hypertension (p < 0.05). We also found an association between anti-topo I and interstitial lung disease in 30.4% of patients. There was no significant association between the positivity for the autoantibodies and other diagnosed clinical manifestations. Conclusion Some clinical manifestations of SSc may correlate positively with the presence of specific autoantibodies. Environmental factors, ethnicity, and gene interaction may also influence this correlation. Lay summary What does this mean for patients? Systemic sclerosis (SSc) is a disease that affects the connective tissues, causing excessive skin and internal organs fibrosis and microvascular damage. Specific autoantibodies, which are antibodies that attack the body's tissues, are responsible for amplifying the immune response and targeting cells involved in the development of SSc. This study aimed to investigate the relationship between specific autoantibodies and the clinical and laboratory features of SSc in 46 Moroccan patients. The majority of patients were female, middle-aged, and of Caucasian ethnicity, with a mean age of 50 years, and duration of disease between 1 and 10 years. The most common symptoms were Raynaud’s phenomenon (89.2% of patients), sclerodactyly (84.8%), proximal scleroderma (67.4%), gastrointestinal involvement (50%), arthralgia (41.3%), interstitial lung disease (30.4%), myalgia (24%) and pulmonary arterial hypertension (10.8%). We found a correlation between anti-RNAP III and Sclerodactyly and pulmonary arterial hypertension, while anti-topo I autoantibodies were associated with interstitial lung disease. The study also noted that environmental factors, ethnicity, and genetic interactions may influence the clinical and autoantibody profile in SSc patients.

show abstract